Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PG4 Pneumococcal Vaccine in Adults
NCT07086677Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Primary completion
- Oct 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PG4 in Streptococcus pneumoniae infection (12 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting prespecified local reactions at 7 days, Percentage of participants reporting prespecified systemic reactions at 7 days and 3 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
PG4
03
Conditions
Streptococcus pneumoniae infection
Beyond the preview
Go deeper on NCT07086677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086677.